Our ongoing series of Drug Pipeline Insights can be accessed from this page. Peruse the links below for the latest commentary, trends, predictions and expert analysis on what's coming to market!
Our Q1 Spotlight focuses on Semaglutide and explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for pharmacy revenues, pricing, and patient access.
2026 Q1 Update: A wave of high-value generic launches—including major diabetes and oncology drugs—signals one of the most commercially impactful years for pharmacy in over a decade
2026 Q1 Update: An increasingly crowded biosimilars market—led by blockbuster biologics like aflibercept and denosumab—creates new competitive dynamics and savings opportunities pharmacies can’t afford to miss.
2026 Q1 Update: From rare disease breakthroughs to cutting-edge oncology therapies, the latest round of new drug approvals and submissions is set to reshape future pharmacy care.
Health Canada Approvals
Our curated weekly snapshot of new and notable drug approvals across a variety of drug classes to keep pharmacy operators in the know.
